NASDAQ · PDSB
PDS Biotechnology Corporation
$1.55+$0.03 (+1.97%)
PDS Biotechnology Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
Loading market information…
NASDAQ · PYPD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
PolyPid Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.28% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
PolyPid Ltd.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of $0.46. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow PolyPid Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Feb 12, 2025 |
| -$1.13-25.56% vs estimate |
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$1.22-14.02% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $12.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.55+$0.03 (+1.97%)
PDS Biotechnology Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
$1.18+$0.02 (+1.72%)
MAIA Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.01% below the high.
$1.53+$0.15 (+10.87%)
Actinium Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.05% below the high.
$1.02$0.00 (0.0%)
Annovis Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.45% below the high.
$2.23-$0.04 (-1.76%)
Veru Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.58% below the high.
$0.85-$0.09 (-9.66%)
Celularity Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.69% below the high.
$3.08-$0.03 (-0.96%)
Evaxion Biotech A/S’s quoted price sits in the lower half of its reported 52-week range, 55.49% below the high.
$0.39-$0.03 (-6.02%)
Reviva Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.47% below the high.
